Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Six Years And Four Trials Later, LABA/ICS Combos Twist Free Of Box Warning

Executive Summary

US FDA concludes that combination products do not increase risk of serious asthma-related events compared to inhaled corticosteroids alone.

You may also be interested in...



FDA Supersizes Its Order For LABA Safety Studies

The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.

FDA Calls For Class-Wide REMS For LABA Asthma Drugs

On top of a class-wide Risk Evaluation and Mitigation Strategy for the long acting beta-2 adrenergic agonist class of asthma drugs, FDA is going to work through its Safe Use partners to monitor whether actual use adjusts based on the new safety measures

US FDA’s Califf: We Don’t Need Much Help From Congress On Rare Diseases

The FDA commissioner also does not want the agency setting goals for rare disease treatment development.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel